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Abstract
Background: Exogenous sex hormones may play a role in meningioma 
development and growth. Thus, transsexual patients being on long‑standing 
hormone replacement therapy (HRT) may be at particular risk for meningioma 
development and growth. Here we present two cases of two male‑to‑female 
transsexual patients taking HRT for an extended period of time with both patients 
requiring surgical treatment at our institution due to multiple growing meningiomas.
Case Description: The first patient was a 50‑year‑old genetic male (male‑to‑female 
transsexual) who presented 7 years after an extensive sex‑change operation 
due to progressive bitemporal visual defects. The patient had been on HRT 
for approximately a decade. Radiological examinations showed a total of four 
meningiomas, one being a large suprasellar meningioma causing the symptoms. 
Three of the four meningiomas were operated on, but the patient’s vision could 
not be saved. Immunohistochemical (IH) analysis of the meningiomas showed 
both estrogen and progesterone receptor expression. The patient continued HRT 
and during follow‑up regrowth of the meningiomas was noted. The second patient 
was a 48‑year‑old genetic male (male‑to‑female transsexual) who had been on 
HRT for two decades and also presented due to left‑sided visual loss. Radiological 
examination showed four meningiomas, one being a left‑sided sinus cavernous 
meningioma causing compression of the visual apparatus. This patient had a 
previous normal head computerized tomography scan dating back 10 years before 
his current presentation. Three of the four meningiomas were operated on with 
a slight improvement in visual acuity. IH analysis showed positive progesterone 
receptor expression but negative estrogen receptor expression.
Conclusion: Radiological screening may be justifiable for transsexual patients with a 
history of long‑standing HRT and special focus should be paid to transsexual patients 
displaying new neurological symptoms or those already diagnosed with a meningioma.
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INTRODUCTION
The role of sex hormones as a risk factor for 
meningioma development and growth has been a topic 
of debate.[4,7] Several factors such as female gender, 
exposure to ionizing radiation, and familial cancer 
predisposition syndromes (e.g., neurofibromatosis type II) 
have been identified to be associated with an increased 
risk of meningiomas.[18] A few previous case reports have 
described rapid development and growth of meningiomas 
in transsexual individuals taking sex‑hormone replacement 
therapy (HRT).[8,9,15,17] On the other side of the spectrum, 
regression meningiomas after discontinuation of HRT 
have also been described.[5,10,17]
Here we report two further cases of transsexual patients 
with long‑standing HRT developing several meningiomas 
and a brief overview of the literature on this topic.
CASE REPORTS
Case 1
A 43‑year‑old genetic male underwent a male‑to‑female 
sex‑change operation. The patient had been taking 
HRT for several years before the sex‑change operation. 
Following surgery, the patient continued HRT, consisting 
of estradiol cream (0.6 mg/g) twice a day and cyproterone 
acetate (Andocur) 50 mg once a day.
This patient presented 7 years later with progressive 
bilateral visual compromise leading to complete left‑sided 
vision loss. Clinical examination showed normal visual 
acuity on the right side (20/20). The left eye could only 
perceive light sensation, and clinical fundus examination 
revealed left‑sided optic disk atrophy, with a dilated pupil 
and a limited direct pupillary light constriction reflex.
The patient was sent to neuroimaging and magnetic 
resonance imaging (MRI) showed a total of four 
meningiomas: (1) a suprasellar meningioma compressing 
the left optic nerve and chiasm causing the patient’s 
symptoms, (2) a small frontobasal midline meningioma 
at the level of cribriform plate, (3) a small frontal 
right‑sided convexity meningioma, and another (4) large 
frontal right‑sided convexity meningioma [Figure 1, upper 
row]. The patient was put on dexamethasone before the 
operation.
Meningiomas 1, 2, and 4 (suprasellar, frontobasal 
midline, frontal right‑sided convexity) could all be 
surgically accessed in one single session with adequate 
results (Simpson grade III for suprasellar and frontobasal 
meningiomas and Simpson grade I for convexity 
meningioma). The histological diagnosis in all these 
meningiomas revealed World Health Organization (WHO) 
grade I tumors with low proliferative index (MIB‑1 <5%). 
Further immunohistochemical (IH) profiling revealed a 
high level of progesterone receptor expression and lower 
level expression of estrogen receptors.
Immediately after surgery, the limited function that had 
been present in the left eye remained unchanged, but 
unfortunately the visual acuity of the right eye acutely 
deteriorated (to light perception only). Postoperative 
head computed tomography (CT) showed no intracranial 
hemorrhage. The patient was taken back to the operating 
room for exploration. Intraoperative finding showed 
acute swelling of the right optic nerve, and a right‑sided 
optic canal decompression and optic nerve sheath 
fenestration were performed. Unfortunately, vision could 
not be restored in the right eye and the patient became 
legally blind since both eyes suffered from compromised 
vision. After close inspection of anesthesiology reports, 
no hypotensive insult before or during the first or second 
operation was noted.
Postoperative MRI showed complete removal of 
(1) suprasellar meningioma, (2) frontobasal midline 
meningioma, and (4) frontal right‑sided convexity 
meningioma [Figure 1, lower row]. Clinical examination 
did not show any improvement in visual function and 
the patient developed bilaterally dilated pupils without 
any pupillary reaction to light. This was corroborated 
by bilateral optic atrophy and bilateral blindness. The 
remainder of the postoperative course was uneventful, 
and HRT was continued.
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Figure 1: Upper row shows the pre‑operative magnetic resonance 
imaging (MRI) showing four meningiomas: (1) a suprasellar 
meningioma, (2) a small frontal midline meningioma in front 
of the suprasellar meningioma, (3) a right‑sided midline frontal 
convexity meningioma, and a (4) large right‑sided frontal convexity 
meningioma. Lower row shows the 1‑week postoperative MRI where 
meningiomas (1), (2), and (4) have been totally removed. Numbers 
1–4 refer to meningiomas as mentioned in the main text
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The patient was followed with sequential imaging, and 
1 year after surgery a repeat MRI showed no regrowth of 
resected meningiomas but slight growth of small frontal 
right‑sided midline convexity meningioma (3) that had 
been left untouched [Figure 2, upper row]. HRT was 
continued unchanged.
At 2 years, postoperative MRI showed regrowth of a (5) new 
suprasellar meningioma and further growth of unoperated 
frontal right‑sided midline convexity meningioma (3). The 
patient was managed expectantly and HRT was continued 
unchanged [Figure 2, middle row].
Four years after operation, another MRI showed 
significant growth of (5) suprasellar meningioma and 
(3) of the previous unoperated right‑sided midline 
frontal convexity meningioma [Figure 2, lower row]. The 
patient’s neurological status has not changed, and the 
patient did not develop any new deficits. This prompted 
a discussion with the patient regarding the safety of his 
HRT, but the patient remained determined to continue 
HRT. Thus, due to progressive growth of meningiomas, a 
second operation has been scheduled.
Case 2
This is a 48‑year old male‑to‑female transsexual (genetic 
male), who had been taking HRT for 21 years before 
neurosurgical presentation. The HRT consisted 
of estradiol cream (1 mg/g) three times a day and 
cyproterone acetate (Andocur) 50 mg once a day.
The patient presented with progressive left‑sided vision 
loss. Clinical examination revealed near‑normal visual 
acuity in the right eye (20/20) but extremely compromised 
visual acuity in the left eye (20/250) with left‑sided 
optic atrophy on fundus examination. A brain MRI was 
obtained that revealed four meningiomas: (1) in the 
left‑sided sinus cavernous, (2) over the left‑sided frontal 
convexity, (3) over the left‑sided temporal convexity, 
and (4) right‑sided tentorial [Figure 3, upper row]. 
Figure 2: Upper row shows the 1‑year postoperative magnetic resonance imaging (MRI) with no regrowth of the operated meningiomas 
(1, 2, 4) and no major growth of the (3) right‑sided midline frontal convexity meningioma. Middle row shows the 2‑year postoperative 
MRI with some growth of (3) right‑sided midline frontal convexity meningioma and growth of a (5) new meningioma in the suprasellar 
space. Lower row shows the 4‑year postoperative MRI showing some growth of the unoperated (3) right‑sided midline frontal convexity 
meningioma and major growth of the (5) new suprasellar meningioma. Numbers 1–4 refer to meningiomas as mentioned in the main text
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Moreover, the patient had undergone a contrast‑enhanced 
head CT 10 years before the current presentation due to 
transient vertigo and the respective CT was assessed as 
completely normal.
Three of the meningiomas (sinus cavernous, left‑sided 
frontal, and temporal) were operated on and the left optic 
nerve was decompressed in the same surgical sitting at 
about 5 months after symptom had started. Surgery was 
successful and achieved Simpson grade I for convexity 
meningiomas and Simpson grade IV for sinus cavernous 
meningioma. Postoperative MRI showed complete 
removal of convexity meningiomas and a reduction in the 
size of sinus cavernous meningioma [Figure 3, lower row]. 
Histopathological diagnosis revealed all meningiomas 
to be of WHO grade I (MIB‑1 <5% in all). IH analysis 
showed positive staining for progesterone receptor 
expression but was negative for staining of estrogen 
receptor expression. Immediately after surgery, the 
patient experienced subjective visual improvement. The 
remainder of the postoperative course was uneventful.
It was recommended to the patient to taper down the 
HRT, but long‑term follow‑up is still lacking.
DISCUSSION
Here we report our observations of long‑term use of 
HRT and the growth of multiple meningiomas in two 
man‑to‑female transsexual patients. In the first patient, 
growth of several meningiomas was noticed (over a 4‑year 
follow‑up following removal) and it seems probable that 
this is related by the use of exogenous HRT. Since the 
patient had not undergone any brain imaging before 
their clinical presentation, we cannot demonstrate the 
causal role of HRT and risk of meningioma development. 
However, given the receptor expression profile of the 
pathological specimen, this explanation appears intuitive. 
The link between exogenous HRT and meningioma is 
further supported in the second case, by the fact that 
the patient had undergone a contrast‑enhanced head 
CT scan 10 years before the discovery of his meningiomas, 
and that CT was read out as completely normal. Thus, 
it seems likely that the exogenous HRT had a role in 
the development and growth of these patients’ multiple 
meningiomas.
Epidemiological studies have revealed that females are 
more likely to develop meningiomas in the second half 
of life, and due to the fact that many meningiomas may 
express progesterone and estrogen receptors, it has been 
hypothesized that both endogenous and exogenous 
sex hormones may increase the risk for meningioma 
development and growth.[2,6,7,11,18] A study showed that 
up to 88% of all meningiomas express progesterone 
receptors and about 40% of tumors express estrogen 
receptors, with no differences in gender of the afflicted 
patients.[12]The first patient’s pathological specimen was 
positive with regard to both estrogen and progesterone 
receptor expression, whereas the second patient’s 
pathological specimen was positive only with regard to 
progesterone receptor expression. Thus, it seems that 
meningiomal sex‑hormone receptor expression per se 
does not account alone for the noted sex differences in 
meningioma risk. Rather, it might be the continuously 
raised levels of sex hormones that directly affect the 
target tissue and induce meningioma growth. This is 
supported by the fact that in the experimental setting 
antiprogesterone treatment reduces meningioma 
volume regardless of progesterone‑receptor expression 
status.[16]
Previous studies have shown an association between HRT 
and risk of meningioma occurrence in post‑menopausal 
women, especially when taking estradiol supplements 
only.[2,3,11]Androgen deprivation therapy in male patients 
with prostate cancer has also been linked to an increased 
development of meningiomas.[13,14] Although we cannot 
show definite proof, it seems plausible that there is an 
association between HRT and risk of meningiomas[1,4,7] 
and it appears to naturally fit this concept that 
meningioma risk would be increased in male‑to‑female 
transsexual patients with long‑standing HRT. The real 
incidence of meningiomas in male‑to‑female transsexuals 
remains, however, unknown. This scenario might 
be an under‑ or overdiagnosed problem. A previous 
study from the Netherlands found that only 3 of 
2810 male‑to‑female transsexual patients were diagnosed 
with meningiomas.[17] The authors further estimated the 
incidence of meningiomas in male‑to‑female transsexuals 
to be 126/100,000 (which appears to be higher than 
expected when compared with the observed incidences 
Figure 3: Upper row shows the pre‑operative magnetic resonance 
imaging (MRI) revealing a total of four meningiomas: (1) left‑sided 
sinus cavernous, (2) left‑sided frontal convexity, (3) left‑sided 
temporal convexity, and (4) right‑sided tentorial. Lower row showing 
immediate postoperative MRI revealing subtotal resection of 
the (1) sinus cavernous meningioma and total removal of the two 
left‑sided convexity meningiomas (2, 3)
Surgical Neurology International 2018, 9:109 http://www.surgicalneurologyint.com/content/9/1/109
of 32.5/100,000 in males and 65/100,000 in females).[17] 
Yet, due to the low incidence and the missing high level 
of supportive evidence, no definitive imaging guidelines 
have been developed and it is probably not reasonable to 
recommend brain MRIs of all male‑to‑female transsexuals. 
It could, however, be justifiable to routinely evaluate 
patients with brain MRI, if these patients are taking 
high‑dose HRT for a prolonged time (e.g., over 10 years).
With this report, we are hoping to raise awareness of this 
problem and to highlight the importance of brain imaging 
in male‑to‑female transsexuals displaying new neurologic 
symptoms that may be related to intracranial processes 
and especially if individuals have already been diagnosed 
with meningiomas. Still, further case–control matched 
epidemiological studies are necessary to determine the 
real risk of meningioma in transsexual persons.
CONCLUSION
The use of exogenous sex hormones may play a role in 
the development and growth of meningiomas. The risk 
may be dose‑dependent, which would suggest that risk 
is especially high in male‑to‑female transsexual patients 
taking high doses of exogenous sex hormones over long 
periods. Radiological screening may be justifiable for 
transsexual patients with a history of long‑standing 
high‑dose exogenous sex‑hormone therapy and special 
focus should be paid to transsexual patients displaying 
new neurological symptoms or those already diagnosed 
with a meningioma.
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